- Moderna maintains its 2025 revenue forecast, projecting earnings between $1.5 billion and $2.5 billion, with an estimate of $2.39 billion.
- Capital expenditures are expected to be approximately $400 million, below the estimate of $468.9 million.
- For the fourth quarter, the company reported a loss per share of $2.91, compared to an earnings per share of 55 cents in the previous year.
- Quarterly revenue fell by 66% year-over-year to $966 million, slightly above the estimate of $954.3 million.
- Revenue from the Covid-19 vaccine was $923 million, closely aligning with the estimate of $922.3 million.
- Total operating expenses decreased by 21% year-over-year to $2.21 billion, near the estimate of $2.18 billion.
- Cost of goods sold was $739 million, a 20% year-over-year decrease, but higher than the estimated $580.5 million.
- Research and development expenses came in at $1.12 billion, below the estimated $1.16 billion.
- Selling, general, and administrative expenses were $351 million, a 25% decline year-over-year, slightly above the estimate of $345.7 million.
- Moderna experienced an operating loss of $1.25 billion, a shift from the previous year’s profit of $6 million, and more than the estimated loss of $1.13 billion.
- The company’s cash and cash equivalents stood at $1.93 billion, below the estimate of $2.12 billion.
- Moderna expects approximately $200 million in revenue for the first half of 2025.
- The company projects the 2025 cost of sales to be about $1.2 billion.
- By the end of the year, Moderna aims to reduce nearly $1 billion in costs.
Moderna on Smartkarma
Analyst coverage on Moderna on Smartkarma is insightful, with Baptista Research providing valuable perspectives on the biotech giant. In the report titled “Moderna In Crisis? A Possible Wake-Up Call That Investors Have Been Dreading!”, the analyst highlights the company’s transformative journey post-pandemic. Despite record-breaking Covid-19 vaccine sales, Moderna faces significant headwinds, leading to a shift in investor sentiment towards caution.
Additionally, Baptista Research‘s report “Moderna Inc.: Expanding Global Presence For Unmatched Impact! – Major Drivers” sheds light on the company’s financial performance. Moderna reported $1.9 billion in revenue, with a net income of $13 million in the third quarter of 2024, showcasing its strong liquidity position with $9.2 billion in cash and investments. This underscores Moderna’s ability to support current and future initiatives, reflecting positively on its growth prospects.
A look at Moderna Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Moderna, Inc. operates as a biotechnology company specializing in the discovery and development of messenger RNA therapeutics and vaccines for various diseases. The company has received positive ratings in several key areas according to Smartkarma Smart Scores. With a high Value score of 4 and Resilience score of 4, Moderna is positioned well for long-term success in terms of undervaluation and stability. However, its lower scores in Dividend and Momentum indicate a lack of focus on dividend payouts and potentially slower short-term price movement.
In terms of growth, Moderna received a score of 2, suggesting moderate growth potential. While the company’s innovative mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases show promise, further improvements in growth strategies may be needed to drive higher scores in this area. Overall, Moderna’s strong emphasis on research and development in the biotechnology sector positions it as a resilient player with solid long-term prospects despite some short-term challenges.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
